SomnoMed Limited

ASX:SOM Stock Report

Market Cap: AU$188.7m

SomnoMed Valuation

Is SOM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

AU$0.86
Fair Value
0.5% overvalued intrinsic discount
3
Number of Analysts

Below Fair Value: SOM (A$0.87) is trading above our estimate of fair value (A$0.86)

Significantly Below Fair Value: SOM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOM?

Key metric: As SOM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SOM. This is calculated by dividing SOM's market cap by their current revenue.
What is SOM's PS Ratio?
PS Ratio1.7x
SalesAU$111.49m
Market CapAU$188.73m

Price to Sales Ratio vs Peers

How does SOM's PS Ratio compare to its peers?

The above table shows the PS ratio for SOM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.8x
EMV EMVision Medical Devices
34.2x16.38%AU$172.8m
AHC Austco Healthcare
1.7x13.52%AU$142.4m
CYC Cyclopharm
3.1x36.66%AU$95.0m
IPD ImpediMed
8x47.89%AU$101.8m
SOM SomnoMed
1.7x8.66%AU$188.7m

Price-To-Sales vs Peers: SOM is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (11.8x).

Price to Sales Ratio vs Industry

How does SOM's PS Ratio compare vs other companies in the AU Medical Equipment Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
SDI SDI
1x6.19%US$70.65m
CMP Compumedics
1.1x18.67%US$36.78m
NXS Next Science
1.4xn/aUS$29.95m
UBI Universal Biosensors
0.7xn/aUS$2.76m
SOM 1.7xIndustry Avg. 6.6xNo. of Companies9PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SOM is good value based on its Price-To-Sales Ratio (1.7x) compared to the Australian Medical Equipment industry average (6.6x).

Price to Sales Ratio vs Fair Ratio

What is SOM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: SOM is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.86
AU$1.00
+15.22%
0.47%AU$1.00AU$0.99n/a3
Sep ’26AU$0.78
AU$1.00
+27.78%
0.47%AU$1.00AU$0.99n/a3
Aug ’26AU$0.83
AU$0.90
+7.78%
11.11%AU$1.00AU$0.80n/a2
Apr ’25AU$0.39
AU$1.26
+227.27%
64.29%AU$2.07AU$0.45AU$0.542
Mar ’25AU$0.40
AU$1.66
+315.00%
24.70%AU$2.07AU$1.25AU$0.602
Feb ’25AU$0.49
AU$1.66
+235.35%
24.70%AU$2.07AU$1.25AU$0.662
Jan ’25AU$0.50
AU$1.66
+232.00%
24.70%AU$2.07AU$1.25AU$0.462
Dec ’24AU$0.44
AU$1.66
+277.27%
24.70%AU$2.07AU$1.25AU$0.392
Nov ’24AU$0.49
AU$1.69
+245.58%
19.96%AU$2.07AU$1.25AU$0.313
Oct ’24AU$0.70
AU$1.94
+175.65%
6.83%AU$2.07AU$1.76AU$0.403
AU$1
Fair Value
13.2% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 14:46
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SomnoMed Limited is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Iain WilkieMorgans Financial Limited
Peter MeichelboeckSelect Equities Pty Ltd
Dennis HulmeTaylor Collison Limited